Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments

Affiliations

• 1 Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
• 2 Department of Applied Biological Sciences, Tokyo University of Science, Noda 278-8510, Japan.
• 3 School of Medicine, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa 920-8640, Japan.
• 4 Department of Analytical Biochemistry, Meiji Pharmaceutical University, Kiyose 204-8588, Japan.
• 5 Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.
• 6 Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan; [email protected] [email protected].
• 7 Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Saitama 332-0012, Japan.
• 8 Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama 332-0012, Japan.
• 9 Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; [email protected] [email protected].